Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
Holding BCDA?
Track your performance easily
BCDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.84 - $10.94
Previous Close$2.14
Volume22.76K
Average Volume (3M)838.51K
Market Cap
$10.54M
Enterprise Value$5.90M
Total Cash (Recent Filing)$4.93M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Apr 01, 2025EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding4,584,285
10 Day Avg. Volume65,915
30 Day Avg. Volume838,512
Standard Deviation0.23
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)3.32
Price to Sales (P/S)131.07
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.22
Enterprise Value/Gross Profit12.37
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$25.00Price Target Upside986.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BioCardia News
PremiumCompany Announcements
BioCardia Reports Q3 2024 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim data from the company’s most advanced program, the Phase 3 CardiAMP HF, demonstrated significant reductions in heart death equivalents and non-fatal MACCE, and exhibited a greater efficacy in patients with elevated baseline NT-proBNP levels.
Financial SupportApproved Medicare reimbursements for the ongoing Phase 3 CardiAMP HF II and CardiAMP CMI trials benefit the company's cash-neutral strategy.
Regulatory ApprovalBiocardia announced that the FDA has approved the protocol amendment for the CardiAMP cell population analysis to be used in the ongoing Phase 3 CardiAMP HF II confirmatory trial in HFrEF patients.
Bears Say
Cash ResourcesCautious about cash resources, Biocardia ended the quarter with $0.95 million in cash.
Efficacy DataThere is an absence of near-term efficacy data readouts and regulatory decisions.
Future OutlookWhile vigilant of the future of the company based on its cash position, absence of near-term efficacy data readouts, and regulatory decisions.
---
Ownership Overview
92.70% Insiders
0.55% Mutual Funds
0.02% Other Institutional Investors
6.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $1.84 and its highest was $10.94 in the past 12 months.
What is BioCardia Inc’s market cap?
Currently, no data Available
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Apr 01, 2025 which is in 129 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Nov 13, 2024. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$1.19 by $0.58.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -$0.87.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 4,584,285 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.61 in its last earnings report, beating expectations of -$1.19. Following the earnings report the stock price went down -14.043%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
---
BioCardia Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (986.96% Upside)
$25.00 (986.96% Upside)
Blogger Sentiment
Bullish
BCDA Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $2.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.40%
12-Months-Change
Fundamentals
Return on Equity
-737.89%
Trailing 12-Months
Asset Growth
67.25%
Trailing 12-Months
Company Description
BioCardia Inc
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
---
BCDA Earnings Call
Q3 2024
0:00 / 0:00
---
BCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(986.96% Upside)
Technical Analysis
Best Analysts Covering BCDA
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-55.95%
reiterated a buy rating 9 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.95% per trade.
---